CustomCustomCustomCustomCustomCustom
4 12, 2025

Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

2025-12-04T11:05:09+01:00December 4th, 2025|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

New research highlights the potential of circulating miRNAs as biomarkers for joint degeneration A new peer-reviewed study has been published in the International Journal of Molecular Sciences (IJMS): “Synovial Fluid and Serum MicroRNA Signatures in Equine Osteoarthritis.” This work provides important insights into how microRNAs (miRNAs) in serum and synovial fluid reflect the presence of osteoarthritis (OA) in horses. 🎯 Study Aim The researchers sought to identify disease-associated miRNAs that differ between healthy horses and horses with osteoarthritis. Their goal was to uncover molecular signatures that could support the development of novel biomarkers for early detection and monitoring of OA. 🔬 Methods Serum and synovial fluid samples were collected from healthy controls (n = 4) and horses [...]

Read More
26 11, 2025

TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

2025-12-04T11:05:55+01:00November 26th, 2025|biomarkers in orthopaedics, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, periprosthetic joint infections, promiR, quality, Synovial fluid|Comments Off on TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

On November 19th, 2025, the study “Synovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections” by Frank et al. was published in the Journal of Bone and Joint Surgery. This peer-reviewed publication marks an important milestone in TAmiRNA’s biomarker development program and presents promiR®, our novel microRNA-based diagnostic panel designed to improve the pre-operative assessment of periprosthetic joint infections (PJIs). Clinical Challenge PJIs remain one of the most serious and difficult complications following total joint replacement. Current diagnostic methods—including inflammatory markers, imaging, and cultures—often lack sensitivity and specificity, especially for low-grade or culture-negative infections. Even advanced approaches such as PCR or next-generation sequencing can suffer from contamination risks and ambiguous [...]

Read More
11 11, 2025

Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

2025-11-11T08:44:13+01:00November 11th, 2025|exosomes, extracellular vesicle, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

Vienna, Austria – November 2025 TAmiRNA scientist have contributed significantly to a new study published by the Ludwig Boltzmann Institute for Traumatology, which is titled “Distinct miRNA profiles in human amniotic tissue and its vesicular and non-vesicular secretome”. The article was published in Frontiers in Cell and Developmental Biology on October 29th 2025. Human amniotic membrane (hAM) has been used in tissue regeneration and wound healing applications. In this study, the miND® small RNA-sequencing workflow was applied to generate fresh insights into the microRNA composition of two spatially and physiologically distinct regions of the human amniotic membrane (hAM) and its secreted extracellular vesicles (EVs) and protein-bound miRNAs. The work highlights how advanced analytical workflows can uncover tissue- [...]

Read More
3 11, 2025

TAmiRNA launches the new lyophilized miND® spike-in kit for small RNA-sequencing quality control

2025-11-03T11:11:21+01:00November 3rd, 2025|miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on TAmiRNA launches the new lyophilized miND® spike-in kit for small RNA-sequencing quality control

Vienna, Austria – November 2025 TAmiRNA proudly announces the release of its miND® spike-in kit in a new lyophilized format, optimized for the preparation and analysis of 96 small RNA-sequencing libraries. This upgraded format improves handling, stability, and integration with standard small RNA-sequencing workflows, ensuring seamless compatibility with commonly used library preparation kits. The new lyophilized miND® spike-in kit combines ease of use and long-term stability with TAmiRNA’s proven spike-in design (5’ and 3’ end randomization) for accurate and reproducible normalization in small RNA-sequencing experiments. The revised 96-reaction format is ideal for medium- to large-scale studies and simplifies quality control across multiple runs. In addition, TAmiRNA has generated new data confirming the robust performance and stability of [...]

Read More
6 09, 2024

TAmiRNA at EUROTOX 2024 in Copenhagen

2024-09-11T08:35:27+02:00September 6th, 2024|biomarker, biomarkers, drug-induced pancreatic injury, microRNAs, miND, miND spike ins, NGS, small RNA-sequencing, TransBioLine|Comments Off on TAmiRNA at EUROTOX 2024 in Copenhagen

On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Dr. Kseniya Khamina-Kotisch, on “NGS-based discovery of microRNA biomarkers of drug-induced pancreatic injury (DIPI),” showcasing the merits of small RNA-sequencing (miND) for biomarker discovery. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

Read More
2 09, 2024

TAmiRNA at SSCC/SGK in Zürich

2024-09-11T08:36:01+02:00September 2nd, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNAs, miND spike ins, NGS|Comments Off on TAmiRNA at SSCC/SGK in Zürich

TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe's first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA's strengths in microRNA diagnostic development. Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present "MicroRNAs as a Novel Class of Biomarkers" on Friday, September 6, in Session 6: New Technologies. He will discuss the critical role of miRNA biomarkers and TAmiRNA's advanced sequencing techniques, which speed up the discovery of novel biomarker associations. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

Read More
18 06, 2024

TAmiRNA at SelectBIO Congress Rotterdam

2024-09-11T08:36:38+02:00June 18th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNAs, miND spike ins, NGS|Comments Off on TAmiRNA at SelectBIO Congress Rotterdam

TAmiRNA CEO/CSO Matthias Hackl and scientst Marianne Pultar will attend the SelectBIO Congress Rotterdam next week and will showcase its services at Booth E5 in the Exhibition Zone at the Hilton Rotterdam. TAmiRNA will also be a scientific contributor to the conference with a poster presentation on how to leverage extracellular vesicle microRNA cargo to enable in-vivo tracing of EVs based on their unique cargoes (biodistribution). Reach out to Matthias and Marianne directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA CEO Dr. Matthias Hackl

Read More
4 04, 2024

Exciting news!

2024-04-04T13:16:30+02:00April 4th, 2024|biomarker, biomarkers, Illumina NewSeq2000, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Exciting news!

We just received the Illumina NextSeq 2000 machine, marking a significant milestone in our journey towards cutting-edge research and innovation. This powerful instrument will drive our NGS services and allow us to deliver results quicker than ever before.

Read More
5 03, 2024

TAmiRNA at RNA Leaders conference in Basel

2024-03-05T08:19:26+01:00March 5th, 2024|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA at RNA Leaders conference in Basel

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Basel next week to speak about the recent development of reliable miRNA safety biomarkers and their potential to indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. Reach out to Matthias directly to meet with him before or after his presentation on Wednesday, March 13th at 12:25 pm and discuss our latest developments and how TAmiRNA's  services can assist your business!

Read More
10 01, 2024

TAmiRNA partners with Techtum Lab

2024-01-10T09:45:03+01:00January 10th, 2024|microRNA, microRNA services, microRNAs, miND spike ins, NGS, PCR testing service, smallRNA, Techtum Lab|Comments Off on TAmiRNA partners with Techtum Lab

TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.

Read More
© Copyright TAmiRNA 2019 - 
Go to Top